如何考量抗菌药物管理干预的更广泛经济价值:成本效果评价的新方法
本文通过非系统性文献综述,指出传统成本效果分析在评价抗菌药物管理干预时的局限,即难以估算对未来人群的间接长期获益。作者提出一种新方法,通过考虑为保护抗生素有效性而需当前付出的牺牲的货币价值,来比较不同管理干预的成本效果,从而绕过对间接长期获益的显式估计。
要点
- 传统成本效果分析难以处理抗菌药物管理干预对未来耐药性的间接长期获益。
- 新方法通过评估当前为保护抗生素有效性所需牺牲的货币价值来间接体现长期获益。
- 该方法务实,有助于在有限预算下合理确定管理干预的优先顺序。
核心结论
- 传统成本效果分析因长期间接获益不确定性大而限制决策,新方法可绕过显式估计间接长期获益来比较管理干预的成本效果。
研究设计与样本
- 非系统性文献综述,识别传统成本效果评价应用于抗菌药物管理干预的关键局限,并提出新方法及工作示例。
主要发现
- 所有抗生素使用均可促进耐药,管理干预通过改善处方产生直接成本和结局变化,并改变长期耐药轨迹产生间接获益。
- 长期获益的不确定性很大,阻碍了分析和决策推断。
临床怎么用
- 新方法务实且必要,可支持在有限预算下合理确定管理干预的优先顺序。
局限性
- 新方法存在局限性和假设,文中进行了讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: All antibiotic use can contribute to antimicrobial resistance. By improving antibiotic prescribing, antimicrobial stewardship interventions can produce direct cost and outcome changes for those receiving the interventions while altering long-term antimicrobial resistance trajectories to generate indirect benefits for future populations. To compare the cost-effectiveness of different antimicrobial stewardship interventions, we have to consider both the short-term direct costs and clinical outcomes and the long-term indirect benefits to future populations. However, uncertainties for the long-term benefits are considerable, which inhibits analyses and decision-making inference. OBJECTIVES: To describe the limitations of conventional cost-effectiveness analyses in evaluating antimicrobial stewardship interventions and propose a novel approach for comparing the cost-effectiveness of different antimicrobial stewardship interventions that bypasses the need to explicitly estimate indirect long-term benefits. SOURCES: We performed a nonsystematic literature review to identify key limitations of conventional cost-effectiveness evaluation when applied to antimicrobial stewardship interventions. CONTENT: We propose a novel approach for evaluating the cost-effectiveness of antimicrobial stewardship interventions that considers the monetary value of present-day sacrifices needed to preserve antibiotic effectiveness for future populations. We illustrate our method with a worked example and discuss the limitations and assumptions surrounding our proposed approach. IMPLICATIONS: Our study responds directly to calls for adapting current health technology assessment methods for interventions with complex externalities. Our proposed method is pragmatic and necessary to support rational prioritization of stewardship interventions under finite budgets.
引用
- Cai Y, Morton A, Graves N, et al. How to consider the broader economic value of antimicrobial stewardship interventions: a novel approach to cost-effectiveness evaluation. Clin Microbiol Infect. 2026. PMID: 42716380. doi:10.1016/j.cmi.2026.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。